Ind-Swift Laboratories Ltd. (IN:INDSWFTLAB)
:INDSWFTLAB
Want to see IN:INDSWFTLAB full AI Analyst Report?
Top Page
Ind-Swift Laboratories Ltd.
(INDSWFTLAB)
Select Model
Select Model
Rating:62Neutral
Price Target:
₹174.00
▲(91.84% Upside)
Action:Reiterated
Date:06/02/26
The score is held back primarily by weakening financial performance—especially three consecutive years of negative operating/free cash flow and recent revenue contraction—despite a materially improved balance sheet. Technicals are supportive with price trading above key moving averages and positive MACD, but valuation (P/E ~33) limits upside given the current fundamental pressure.
Positive Factors
Reduced leverage and stronger capital base
The company materially lowered leverage and grew equity through 2024–2026, creating a stronger capital base that reduces refinancing risk and improves financial flexibility. This durable improvement provides room to fund restructuring or targeted investments without immediate liquidity stress, though one-time actions should be monitored.
Negative Factors
Three consecutive years of negative operating/free cash flow
Persistent negative operating and free cash flow over multiple years drains liquidity and forces reliance on balance-sheet measures or external funding. This structural cash shortfall constrains investment, capital allocation, and buffer against shocks, increasing refinancing and execution risk unless cash conversion is sustainably restored.
Read all positive and negative factors
Positive Factors
Negative Factors
Reduced leverage and stronger capital base
The company materially lowered leverage and grew equity through 2024–2026, creating a stronger capital base that reduces refinancing risk and improves financial flexibility. This durable improvement provides room to fund restructuring or targeted investments without immediate liquidity stress, though one-time actions should be monitored.
Read all positive factors
Ind-Swift Laboratories Ltd. (INDSWFTLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹14.63B
Dividend YieldN/A
Average Volume (3M)7.30K
Price to Earnings (P/E)34.0
Beta (1Y)0.92
Revenue Growth226.01%
EPS Growth-84.17%
CountryIN
Employees47
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)44.44
Shares Outstanding86,836,555
10 Day Avg. Volume7,859
30 Day Avg. Volume7,299
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)0.79
Price to Sales (P/S)1.71
P/FCF Ratio-10.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ind-Swift Laboratories Ltd. Business Overview & Revenue Model
Company Description
Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, includ...
How the Company Makes Money
null...
Ind-Swift Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
72
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Mar 2026 | Jun 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.22B | 6.41B | 5.62B | 12.81B | 12.07B | 10.39B |
| Gross Profit | 4.19B | 1.90B | 2.74B | 4.13B | 4.40B | 4.10B |
| EBITDA | 3.05B | 450.97M | 2.85B | 7.82B | 2.36B | 2.35B |
| Net Income | 2.66B | 414.15M | 2.50B | 4.21B | 475.97M | -21.49M |
Balance Sheet | ||||||
| Total Assets | 15.44B | 16.73B | 14.38B | 14.60B | 18.24B | 18.01B |
| Cash, Cash Equivalents and Short-Term Investments | 4.33B | 4.72B | 4.82B | 4.94B | 231.54M | 333.68M |
| Total Debt | 220.47M | 205.01M | 408.41M | 166.22M | 8.62B | 9.53B |
| Total Liabilities | 2.37B | 2.89B | 2.65B | 6.48B | 11.42B | 12.00B |
| Stockholders Equity | 13.07B | 13.84B | 11.73B | 9.36B | 6.82B | 6.01B |
Cash Flow | ||||||
| Free Cash Flow | -472.94M | -1.08B | -898.80M | -2.08B | 1.82B | 1.32B |
| Operating Cash Flow | -202.50M | -198.64M | -254.74M | -1.63B | 1.95B | 1.50B |
| Investing Cash Flow | -1.04B | -1.28B | -1.10B | -1.23B | -133.68M | 47.72M |
| Financing Cash Flow | 961.18M | 1.47B | 692.05M | 6.99B | -1.86B | -1.41B |
Ind-Swift Laboratories Ltd. Technical Analysis
Positive
90.70
Price Trends
144.82
Positive
138.76
Positive
119.01
Positive
Market Momentum
6.59
Negative
68.84
Neutral
66.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDSWFTLAB, the sentiment is Positive. The current price of 90.7 is below the 20-day moving average (MA) of 153.94, below the 50-day MA of 144.82, and below the 200-day MA of 119.01, indicating a bullish trend. The MACD of 6.59 indicates Negative momentum. The RSI at 68.84 is Neutral, neither overbought nor oversold. The STOCH value of 66.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:INDSWFTLAB.
Ind-Swift Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹23.55B | 22.61 | ― | ― | 17.97% | 126.79% | |
73 Outperform | ₹12.24B | 13.87 | ― | 0.37% | 7.67% | 6.74% | |
62 Neutral | ₹14.63B | 34.01 | ― | ― | 226.01% | -84.17% | |
52 Neutral | ₹27.10B | -334.22 | ― | ― | 6.64% | -177.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ₹24.48B | -50.09 | ― | 0.58% | -7.91% | -153.72% | |
43 Neutral | ₹21.41B | -20.11 | ― | 0.08% | 10.73% | -31.79% |
* Healthcare Sector Average
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
168.50
61.84
57.98%
IN:HIKAL
Hikal Limited
198.50
-159.88
-44.61%
IN:INDOCO
Indoco Remedies Limited
231.90
-52.40
-18.43%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
611.05
51.50
9.20%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
567.95
37.25
7.02%
IN:VENUSREM
Venus Remedies Limited
1,761.65
1,329.30
307.46%
Ind-Swift Laboratories Ltd. Corporate Events
Ind-Swift Laboratories Seeks Shareholder Nod for Major Leadership Restructuring via Postal Ballot
Mar 30, 2026
Ind-Swift Laboratories Ltd. has launched a postal ballot process to seek shareholder approval for several key board and management changes, underscoring a significant reshaping of its leadership structure across domestic and global operations. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.